Special Report: Regenerative medicine company Regeneus has secured seasoned industry leaders to its board as it looks to make bigger noise overseas.

Regeneus Ltd (ASX: RGS), a leading pain management and clinical-stage regenerative medicine company, has fast-tracked its push for global growth following the appointments of two highly successful leaders in life sciences and biotechnology to its board.

Both Dr John Chiplin, PhD and Dr. Alan Dunton, M.D, bring significant experience and a successful track record in leading and scaling high-growth life sciences and biotechnology companies internationally, with their appointments effective as of 29 April 2019.

Commenting on the announcement, Regeneus Chief Executive Officer Leo Lee said John and Alan’s appointments were a game-changer for the company as it looks to build on the strength of its highly-scalable flagship solutions, Progenza and Sygenus, and their potential to change people’s lives across the world.

“Dr Chiplin’s deep experience in raising capital internationally and strategic guidance will prove invaluable to us and Dr Dunton’s wealth of knowledge in commercialising drugs on a global scale places Regeneus in a strong position to create a huge uplift in value for shareholders,” Lee added.

Lee underlined his growth ambitions for Regeneus, saying the board now possessed the right mix of leadership capabilities and industry nous to tackle a wealth of emerging opportunities in servicing the neuropathic pain market worldwide.

“I am very pleased to welcome both Alan and John to the Board to support us through the Company’s next phase of growth and commercialisation,” he said.

“This is a tremendous time for Regeneus, their appointments bring invaluable experience to support us through our next phase of growth, particularly as we focus on commercialising our technology to address the huge and growing global pain market.”

Solid experience in sourcing global capital

For almost two decades, Dr John Chiplin served as CEO at three leading publicly-listed software, biotechnology and cancer immunotherapy companies. He has a wealth of experience in operational, investment and transactions across the international life science and technology sectors.

“Regeneus is now entering its next phase, as it looks to accelerate its growth globally and raise the capital required to support the commercialisation of its technology platforms,” he said.

“I am looking forward to playing a strategic role in helping the Company access global capital, to fund an accelerated growth strategy into global pain markets.”

Deep industry knowledge

Dr Alan Dunton is a pharmaceutical and biotechnology industry leader with over 35 years of experience in senior company leadership roles, spanning pharmaceutical research and development to private biotechnology companies focussed on prescriptive treatment and the commercialisation of over-the-counter drugs on a global scale.

“I see great potential for this technology to address a large, global pain market and am excited to join the Board to help support the Company’s global growth plans and commercialise these technologies,” he said.

Changing of the guard

Regeneus also announced current board members, Roger Aston and John Martin, will step down from their roles as Non-Executive Chairman and Non-Executive Director respectively.

The company confirmed Barry Sechos will step into the role of Non-Executive Chairman, effective 29 April 2019.

Tapping into a US$79 billion opportunity

Figures from Datamonitor Healthcare – Neuropathic Pain Market Spotlight 2018 show the global neuropathic pain market alone is estimated to be worth US$69 billion.

The data revealed a total of 425.2 million prevalent cases of neuropathic pain in adults aged 20 years and older worldwide, with forecasts showing that number is set to rise up to 476.2 million cases by 2026.

The report found the global neuropathic pain market could reach a total of US$79 Billion by 2024 – an opportunity Regeneus looks set to capture with these exceptional new hires.

>> NOW WATCH: Regeneus CEO Leo Lee talk about the potential impact of the new board members. 

This story was developed in collaboration with Regeneus Ltd, a Stockhead advertiser at the time of publishing.
This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice. If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a disclosure document, a Product Disclosure Statement or an offer document (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.